New HIV vaccine shows promise in early human trial
NCT ID NCT04915768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new HIV vaccine in 51 healthy adults to see if it is safe and triggers an immune response. The vaccine aims to train the body to produce special antibodies that can fight HIV. Researchers also tested different combinations of adjuvants (ingredients that boost the immune response) to find the best balance of effectiveness and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's CRS
Boston, Massachusetts, 02115, United States
-
The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, 30030, United States
-
Vanderbilt Vaccine (VV) CRS
Nashville, Tennessee, 30030, United States